Plain-English translation of NCT06643819 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This Phase 3 trial is testing a medication called Sacubitril∙ to see if it effectively lowers blood pressure and is safe for people with high blood pressure. Researchers want to confirm that this treatment works better than or as well as similar medications already available. About 324 people will participate across multiple medical centers.
High blood pressure affects millions of people worldwide, and doctors need reliable treatment options. This trial is designed to confirm whether this medication is a safe and effective choice for managing blood pressure in adults.
You likely qualify if…
You likely don't qualify if…
Participants will take the study medication daily and visit the clinic multiple times over the course of the trial for blood pressure checks and safety monitoring. Some participants will receive the new medication, while others will receive a similar active blood pressure drug currently on the market, so researchers can compare how well each works. The study is double-blind, meaning neither you nor the researchers will know which medication you're taking.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
South Korea
Phase
Large-scale testing
Sponsor
Chong Kun Dang Pharmaceutical
Enrollment target
~324 participants
Started
October 2024
Primary completion
March 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
19 Years and older
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Keehyun Ham, Project Leader
Chong Kun Dang Pharmaceutical
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.